Tempus AI Teams Up with United Therapeutics to Tackle Pulmonary Hypertension Using AI

Tempus AI, Inc.has announced a groundbreaking collaboration with biotechnology giant United Therapeutics (UT) to develop AI-powered medical software for early detection of pulmonary hypertension (PH).

The partnership aims to address the critical issue of delayed diagnosis in PH, a fatal and progressive heart and lung disease affecting approximately 1% of the population. Despite available treatments, PH diagnosis is often delayed by two or more years.

Tempus has developed an algorithm that analyzes 12-lead electrocardiogram (ECG) results to identify patients at risk of undiagnosed PH. The company recently presented initial findings at the American Thoracic Society International Conference in San Diego on May 22, 2024.

The research program will utilize Tempus Next, the company's AI-enabled care pathway intelligence solution, to deploy the algorithm at participating centers. Up to 60 centers will be involved in a prospective clinical study to evaluate the algorithm's effectiveness in detecting at-risk patients and tracking clinical outcomes.